• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Twenty new members join DF/HCC community

Twenty individuals from our seven member institutions have recently joined DF/HCC. See below to learn more about these scientists and their research interests.

Hans Olov Adami

Hans-Olov Adami, MD, PhD (HSPH)
Prostate Cancer Program, Cancer Epidemiology Program

Research focus: ranges from genetic association studies to randomized trials of radical surgical treatment, and prediction of outcome using molecular and genetic markers), malignant lymphomas, cervical cancer (with a focus on viral load as a possible determinant of progression from precursors to invasive cancer), and breast cancer.

James Bradner

James E. Bradner, MD, MSc (DFCI)
Lymphoma and Myeloma Program; Translational Pharmacology and Early Therapeutic Trials Program

Research focus: concerns the identification of selective small molecules antagonizing enzymatic components of chromatin remodeling complexes. He is using forward chemical genetic approaches to explore protein catabolism in the cancer cell. The primary focus of his clinical work is the early-phase development of targeted strategies in hematology.

Cheryl Clark

Cheryl Clark, MD, MS, ScD (BWH)
Cancer Epidemiology Program; Cancer Disparities Program

Research focus: social determinants of health as explanatory factors for racial and ethnic disparities in cancer outcomes. A specific area of interest includes basic social science and epidemiologic research to understand neighborhood and area-level determinants of racial and ethnic disparities in prostate cancer outcomes. Additional work includes a case-management intervention to improve screening and abnormal follow up for breast and cervical cancer screening among black women.

Adan Colon-Carmona

Adán Colón-Carmona, BA, PhD (UMB)
Cancer Cell Biology Program

Research focus: understanding how plant growth is influenced by physical and chemical environments, studying the roles of the motor proteins kinesins in organ development, and focusing on understanding bacterial-plant interactions in the rhizosphere of plants.

Thomas Deisboeck

Thomas Deisboeck, MD (MGH)
Invasion, Metastasis, and Angiogenesis Program; Neuro-Oncology Program

Research focus: integrative cancer biology, and the uses of a variety of in silico approaches to model, simulate, and predict cancer growth and invasion by following a systems biology approach that understands a tumor as a complex dynamic, self-organizing biosystem where molecular-level events can percolate across the scales and impact macroscopic behavior. At the molecular level, interests include EGFR and -related pathways and their role in high-grade gliomas.


Jeffrey A. Engelman, MD, PhD (MGH)
Lung Cancer Program

Research focus: determining the most effective targeted therapy (or therapies) that will be effective for killing a particular cancer cell.



Omid Farokhzad, MA, MD (BWH)
Prostate Cancer Program

Research focus: the development and engineering of smart nanoparticles for therapeutic and diagnostic applications. Other areas of focus include drug target identification and validation; and high throughput synthesis and screening of nanomaterials for drug delivery.


Hanno Hock

Hanno Hock, MD, PhD (MGH)
Leukemia Program

Research focus: the transcriptional regulation of normal blood cell development and leukemia, with an emphasis on three transcription factors: the Ets-related transcription factor Tel/Etv6 and the zinc-finger transcription factor Gfi-1, both critical for maintaining HSCs in the bone marrow, and the leukemia translocation-associated hybrid transcription factor Tel-Aml1.


Jim C. Hu, MD, MPH (BWH)
Prostate Cancer Program; Outcomes Research Program

Research focus: the utilization, complications, and length of stay for laparoscopic vs. open radical prostatectomy and whether surgeon volume is associated with better laparoscopic radical prostatectomy outcomes.



Vicki R. Kelley, PhD (BWH)
Cancer Immunology Program

Research focus: the molecular and cellular mechanisms of autoimmune disease and inflammation, and identifying the events that lead to leukocytic accumulation in the tissues, to ultimately identify therapeutic targets.



Phillip Kraft, BA, MS, PhD (HSPH)
Cancer Epidemiology Program, Biostatistics Program

Research focus: statistical methodology in genetic epidemiology, including family-based and population-based case-control studies, currently concentrating on design and analysis of genome-wide association studies.



Susumu Kobayashi, MD, PhD (BIDMC)
Lung Cancer Program

Research focus: the role of the EGF receptor (EGFR) in non-small cell lung cancer (NSCLC) development and the establishment of novel therapies. In particular, Dr. Kobayashi is interested in identifying the main effectors responsible for tyrosine kinase inhibitors (TKIs)-induced apoptosis and exploring alternative strategies for overcoming primary and secondary resistance to TKI therapy.



David S. Ludwig, MD, PhD (CHB)
Cancer Risk Reduction Program

Research focus: the effects of dietary composition on obesity and related diseases (including cancer).


Jennifer Moye

Jennifer A. Moye, PhD (HMS)
Cancer Survivorship Program

Research focus: older patients’ psychological adaptation to medical illness with a specific focus on the medical decision making process in patients with neurocognitive or neuropsychiatric illnesses.

Peter Park

Peter J. Park, PhD (HMS)
Cancer Genetics Program; Biostatistics Program

Research focus: the development of computational methods, high-throughput genomic technologies and their application to the study of epigenetic mechanisms. This includes identification of sites for protein-DNA binding, DNA methylation, and histone modification using chromatin immunoprecipitation on tiling microarrays (ChIP-chip) and detection of chromosomal aberrations using array comparative genomic hybridization (CGH).


Donald R. Senger, PhD (BIDMC)
Invasion, Metastasis, and Angiogenesis Program

Research focus: defining the signaling pathways and cytoskeletal-related mechanisms that control the organization of endothelial cells into new blood vessels within tumors.


Jagesh Shah

Jagesh V. Shah, BS, PhD, SM (HMS)
Kidney Cancer Program

Research focus: the links between the primary cilium and mitotic orientation through the development of microtechnology-based in vitro cell culture models to mimic the ductal microenvironment.

Yu-Tzu Tai

Yu-Tzu Tai, PhD (DFCI)
Lymphoma and Myeloma Program; Translational Pharmacology and Early Therapeutic Trials Program

Research focus: investigating the biological significance of CS1 in MM cell adhesion, growth and survival using comprehensive approaches including lentivirus siRNA targeting CS1 as well as generating CS1-overexpressing vs. knockout mice.


Rulla M. Tamimi, BS, MS, ScD (BWH)
Breast Cancer Program, Cancer Epidemiology Program

Research focus: developing a better understanding of breast cancer risk by utilizing molecular markers and focusing on intermediate endpoints in epidemiologic studies.


Jonathon Winickroff

Jonathan P. Winickoff, CLC, MD, MPH (HMS)
Cancer Risk Reduction Program

Research focus: health services research, medical ethics, neurobiology, statistics, and behavioral theory related to anti-smoking.